Loading...
More information
An antibody-drug conjugate to treat breast cancer
Creating value for patients
Building on good treatments to make them even better
More information
A new medicine is being studied, which combines two powerful anti-cancer approaches: The antibody component blocks the signals that make HER2-positive cancer cells more aggressive and also sends a message to the patient’s immune system to destroy cancer cells. It also delivers a potent chemotherapy agent directly to the tumour cells to induce cell death.
The new medicine may offer patients with HER2-positive breast cancer effective treatment that would spare them the burden and side effects of conventional chemotherapy.
The EMILIA trial compares the new investigational drug against a standard combination treatment with chemotherapy. In addition, the medicine is also being tested in trials with another next-generation antibody therapy by Roche.
1970s
Nonspecific chemotherapy agents:
Chemotherapy attacks both healthy and cancerous cells
Points of attack
Cancer cell
Healthy cell
1970s
2000
Biochemical drug and chemotherapy:
A monoclonal antibody specifically targets HER2-positive tumour cells
Points of attack
Cancer cell
Healthy cell
Nonspecific chemotherapy agents:
Chemotherapy attacks both healthy and cancerous cells
Biochemical drug and chemotherapy:
A monoclonal antibody specifically targets HER2-positive tumour cells
1970s
2000
The future?
New investigational drug:
Attacks cancer cells only, without conventional chemotherapy burden
Points of attack
Cancer cell
Healthy cell
ALECARDIO study in patients with type 2 diabetes and a recent acute coronary syndrome (ACS)
Creating value for patients
Focusing on the unsolved issues
More information
For patients with type 2 diabetes (T2D), blood glucose control is no longer their biggest concern. More than 60% of patients with diabetes die from heart disease and stroke, not from an inability to control blood glucose. And 10% of patients who experience an acute coronary syndrome (ACS) event, such as a heart attack, die within one year.
Currently there is no drug on the market targeting Type 2 Diabetes that specifically and effectively controls the high risk of subsequent cardiovascular morbidity and mortality.
ALECARDIO, a global clinical trial with some 6000 patients, is now testing the hypothesis that the new compound can reduce cardiovascular morbidity and mortality in patients with type 2 diabetes who have suffered a recent ACS event.
Conventional trial in people with type 2 diabetes:
Focuses almost exclusively on controlling patients blood glucose levels:
Blood glucose levels
Conventional trial in people with type 2 diabetes:
Focuses almost exclusively on controlling patients blood glucose levels:
Blood glucose levels
Roche trial in type 2 diabetes high risk subpopulation:
Focuses on reducing cardiovascular risk in people with type 2 diabetes
Blood glucose levels
Hypertension
Blood fats
Reduction of cardiovascular risks
Conventional trial in people with type 2 diabetes:
Focuses almost exclusively on controlling patients blood glucose levels:
Blood glucose levels
Roche trial in type 2 diabetes high risk subpopulation:
Focuses on reducing cardiovascular risk in people with type 2 diabetes
Blood glucose levels
Hypertension
Blood fats
Reduction of cardiovascular risks
Conventional trial in people with type 2 diabetes:
Focuses almost exclusively on controlling patients blood glucose levels:
Blood glucose levels
Roche trial in type 2 diabetes high risk subpopulation:
Focuses on reducing cardiovascular risk in people with type 2 diabetes
Blood glucose levels
Hypertension
Blood fats
Reduction of cardiovascular risks
HPV DNA Test
Creating value for patients
Proving the medical value of a diagnostic test in a rigorous clinical trial
More Information
Persistent infection with human papillomavirus (HPV) is the leading cause of cervical cancer, implicated in more than 99 percent of all cases. Screening enables early identification and removal of pre-cancerous lesions, dramatically reducing the incidence and mortality of cervical cancer worldwide.
The most commonly used test to detect cervical cancer is the “Pap smear” – but thousands of women ultimately diagnosed with cervical cancer had normal Pap smear results.
The Roche ATHENA trial enrolled over 47,000 women, screening participants for cervical cell changes using both the Pap smear and the HPV DNA Test for 14 high-risk HPV genotypes.
Collaborations with research
groups in academia and industry
Biomarker identification
and clinical validation
Show sensitivity and
specificity
ATHENA trial to demonstrate medical value in 47'000 women
Potential new
diagnostic test
Collaborations with research
groups in academia and industry
Biomarker identification
and clinical validation
Show sensitivity and
specificity
ATHENA trial to demonstrate medical value in 47'000 women
Potential new
diagnostic test
Collaborations with research
groups in academia and industry
Biomarker Identification
and clinical validation
Show sensitivity and
specificity
ATHENA trial to demonstrate medical value in 47'000 women
Potential new
diagnostic test
Collaborations with research
groups in academia and industry
Biomarker Identification
and clinical validation
Show sensitivity and
specificity
ATHENA trial to demonstrate medical value in 47'000 women
Potential new
diagnostic test
Collaborations with research
groups in academia and industry
Biomarker Identification
and clinical validation
Show sensitivity and
specificity
ATHENA trial to demonstrate medical value in 47'000 women
The HPV DNA Test may enable physicians to identify women with cervical pre-cancer that are missed using cytology alone.
Potential new
diagnostic test
Phase IV clinical trials in advanced colorectal cancer
Creating value for patients
Doing post-approval trials so an effective medicine can benefit an even wider population
More information
Nearly a million patients have been treated with Avastin since it was first launched in 2004, and this breakthrough cancer medicine is being developed further in an extensive clinical trial programme. Cancer treatment is constantly evolving as oncologists try new drug combinations. Phase IV clinical trials, conducted after a medicine has entered the market, can generate valuable new insights, even for a drug as thoroughly studied as Avastin.
Phase IV trials provide important additional information on safety and efficacy in the ‘real-life’ setting of routine oncology practice, and on the use of Avastin in special populations, such as the elderly. Many phase IV trials are further evaluating Avastin in patients with metastatic colorectal cancer. Some are designed to determine the optimal duration of treatment, while others are investigating new combinations of Avastin with other medicines.
Duration of treatment
New chemotherapy combinations
Broader and more diverse population
Phase IV clinical trials, conducted after
a medicine has entered the market, can generate valuable new insights, even for
a drug thorougly studied.
Duration of treatment
New chemotherapy combinations
Broader and more diverse population
Phase IV clinical trials, conducted after a medicine has entered the market, can generate valuable new insights, even for a drug thorougly studied.
Duration of treatment
New chemotherapy combinations
Broader and more diverse population
Phase IV clinical trials, conducted after a medicine has entered the market, can generate valuable new insights, even for a drug thorougly studied.
Duration of treatment
New chemotherapy combinations
Broader and more diverse population
Phase IV clinical trials, conducted after a medicine has entered the market, can generate valuable new insights, even for a drug thorougly studied.
Duration of treatment
New chemotherapy combinations
Broader and more diverse population
Phase IV clinical trials, conducted after a medicine has entered the market, can generate valuable new insights, even for a drug thorougly studied.
A new approach to treat schizophrenia
Creating value for patients
Having the courage to go where needs are great and hurdles are high
More information
Affecting nearly 24 million people worldwide, schizophrenia is a severe mental disorder that distorts the way a person thinks, acts, expresses emotions, perceives reality and relates to others. It is a lifelong disease that cannot be cured and on average it shortens life expectancy by 20 years due to the higher risk of suicide and also due to cardiovascular and pulmonary events.
Because of negative symptoms, which usually have the greatest impact on quality of life, patients may be unable to live independently, hold jobs, establish personal relationships and manage everyday social situations.
A glycine reuptake inhibitor (GRI) developed at Roche represents a novel approach by treating negative symptoms of schizophrenia.
Available therapies to treat schizophrenia are effective against positive symptoms:
- Hallucinations
- Delusions
- Thought disorder
- Bizarre behaviour
- Disorganised speech
With significant side effects
A new investigational drug to treat schizophrenia may be effective against negative symptoms:
- Social withdrawal
- Self neglect
- Lack of drive
- Apathy
- Affective flattening
With potentially less side effects
Available therapies to treat schizophrenia are effective against positive symptoms:
- Hallucinations
- Delusions
- Thought disorder
- Bizarre behaviour
- Disorganised speech
With significant side effects
A new investigational drug to treat schizophrenia may be effective against negative symptoms:
- Social withdrawal
- Self neglect
- Lack of drive
- Apathy
- Affective flattening
With potentially less side effects
Available therapies to treat schizophrenia are effective against positive symptoms:
- Hallucinations
- Delusions
- Thought disorder
- Bizarre behaviour
- Disorganised speech
With significant side effects
A new investigational drug to treat schizophrenia may be effective against negative symptoms:
- Social withdrawal
- Self neglect
- Lack of drive
- Apathy
- Affective flattening
With potentially less side effects
Available therapies to treat schizophrenia are effective against positive symptoms:
- Hallucinations
- Delusions
- Thought disorder
- Bizarre behaviour
- Disorganised speech
With significant side effects
A new investigational drug to treat schizophrenia may be effective against negative symptoms:
- Social withdrawal
- Self neglect
- Lack of drive
- Apathy
- Affective flattening
With potentially less side effects
Available therapies to treat schizophrenia are effective against positive symptoms:
- Hallucinations
- Delusions
- Thought disorder
- Bizarre behaviour
- Disorganised speech
With significant side effects
A new investigational drug to treat schizophrenia may be effective against negative symptoms:
- Social withdrawal
- Self neglect
- Lack of drive
- Apathy
- Affective flattening
With potentially less side effects
Available therapies to treat schizophrenia are effective against positive symptoms:
- Hallucinations
- Delusions
- Thought disorder
- Bizarre behaviour
- Disorganised speech
With significant side effects
A new investigational drug to treat schizophrenia may be effective against negative symptoms:
- Social withdrawal
- Self neglect
- Lack of drive
- Apathy
- Affective flattening
With potentially less side effects
Available therapies to treat schizophrenia are effective against positive symptoms:
- Hallucinations
- Delusions
- Thought disorder
- Bizarre behaviour
- Disorganised speech
With significant side effects
A new investigational drug to treat schizophrenia may be effective against negative symptoms:
- Social withdrawal
- Self neglect
- Lack of drive
- Apathy
- Affective flattening
With potentially less side effects
Available therapies to treat schizophrenia are effective against positive symptoms:
- Hallucinations
- Delusions
- Thought disorder
- Bizarre behaviour
- Disorganised speech
With significant side effects
A new investigational drug to treat schizophrenia may be effective against negative symptoms:
- Social withdrawal
- Self neglect
- Lack of drive
- Apathy
- Affective flattening
With potentially less side effects
Available therapies to treat schizophrenia are effective against positive symptoms:
- Hallucinations
- Delusions
- Thought disorder
- Bizarre behaviour
- Disorganised speech
With significant side effects
A new investigational drug to treat schizophrenia may be effective against negative symptoms:
- Social withdrawal
- Self neglect
- Lack of drive
- Apathy
- Affective flattening
With potentially less side effects
Available therapies to treat schizophrenia are effective against positive symptoms:
- Hallucinations
- Delusions
- Thought disorder
- Bizarre behaviour
- Disorganised speech
With significant side effects
A new investigational drug to treat schizophrenia may be effective against negative symptoms:
- Social withdrawal
- Self neglect
- Lack of drive
- Apathy
- Affective flattening
With potentially less side effects
Available therapies to treat schizophrenia are effective against positive symptoms:
- Hallucinations
- Delusions
- Thought disorder
- Bizarre behaviour
- Disorganised speech
With significant side effects
A new investigational drug to treat schizophrenia may be effective against negative symptoms:
- Social withdrawal
- Self neglect
- Lack of drive
- Apathy
- Affective flattening
With potentially less side effects
Available therapies to treat schizophrenia are effective against positive symptoms:
- Hallucinations
- Delusions
- Thought disorder
- Bizarre behaviour
- Disorganised speech
With significant side effects
A new investigational drug to treat schizophrenia may be effective against negative symptoms:
- Social withdrawal
- Self neglect
- Lack of drive
- Apathy
- Affective flattening
With potentially less side effects
Available therapies to treat schizophrenia are effective against positive symptoms:
- Hallucinations
- Delusions
- Thought disorder
- Bizarre behaviour
- Disorganised speech
With significant side effects
A new investigational drug to treat schizophrenia may be effective against negative symptoms:
- Social withdrawal
- Self neglect
- Lack of drive
- Apathy
- Affective flattening
With potentially less side effects
Available therapies to treat schizophrenia are effective against positive symptoms:
- Hallucinations
- Delusions
- Thought disorder
- Bizarre behaviour
- Disorganised speech
With significant side effects
A new investigational drug to treat schizophrenia may be effective against negative symptoms:
- Social withdrawal
- Self neglect
- Lack of drive
- Apathy
- Affective flattening
With potentially less side effects
Available therapies to treat schizophrenia are effective against positive symptoms:
- Hallucinations
- Delusions
- Thought disorder
- Bizarre behaviour
- Disorganised speech
With significant side effects
A new investigational drug to treat schizophrenia may be effective against negative symptoms:
- Social withdrawal
- Self neglect
- Lack of drive
- Apathy
- Affective flattening
With potentially less side effects
Clinical development: a long process that continues even after market launch
Creating value for patients
Investing skill and resources in a long, uncertain journey
1,000,000,000 CHF investment
7,000,874 hours of work
6,587 experiments
423 researchers
1 drug
1,000,000,000 CHF investment
7,000,874 hours of work
6,587 experiments
423 researchers
1 drug
1,000,000,000 CHF investment
7,000,874 hours of work
6,587 experiments
423 researchers
1 drug
1,000,000,000 CHF investment
7,000,874 hours of work
6,587 experiments
423 researchers
1 drug
Watch the
video
video
1,000,000,000 CHF investment
7,000,874 hours of work
6,587 experiments
423 researchers
1 drug
| Did you find this feature informative? | No | Yes |
|---|
Please feel free to leave additional comments: